Anixa Biosciences (ANIX) 10-Q 10 Jun 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Apr. 30, 2022	Jun. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--10-31
Entity File Number	001-37492
Entity Registrant Name	ANIXA BIOSCIENCES, INC.
Entity Central Index Key	0000715446
Entity Tax Identification Number	11-2622630
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3150 Almaden Expressway
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95118
City Area Code	(408)
Local Phone Number	708-9808
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	ANIX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,471,001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2022	Oct. 31, 2021
Current assets:
Cash and cash equivalents	$ 27,732	$ 29,128
Short-term investments	4,499	6,599
Prepaid expenses and other current assets	332	276
Total current assets	32,563	36,003
Operating lease right-of-use asset	234	254
Total assets	32,797	36,257
Current liabilities:
Accounts payable	93	136
Accrued expenses	1,057	1,095
Operating lease liability	39	39
Total current liabilities	1,189	1,270
Operating lease liability, non-current	202	220
Total liabilities	1,391	1,490
Commitments and contingencies (Note 9)
Shareholders’ equity:
Preferred stock
Common stock, par value $.01 per share; 100,000,000 shares authorized; 30,154,708 and 30,050,894 shares issued and outstanding as of April 30, 2022 and October 31, 2021, respectively	302	301
Additional paid-in capital	244,032	239,927
Accumulated deficit	(212,163)	(204,790)
Total shareholders’ equity	32,171	35,438
Noncontrolling interest (Note 1)	(765)	(671)
Total equity	31,406	34,767
Total liabilities and equity	32,797	36,257
Series A Convertible Preferred Stock [Member]
Shareholders’ equity:
Preferred stock

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2022	Oct. 31, 2021
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,154,708	30,050,894
Common stock, shares outstanding	30,154,708	30,050,894
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Income Statement [Abstract]
Revenue				$ 513
Operating costs and expenses:
Inventor royalties, contingent legal fees, litigation and licensing expenses				385
Research and development expenses (including non-cash share-based compensation expenses of $966, $447, $2,243 and $737, respectively)	1,735	1,022	3,573	1,850
General and administrative expenses (including non-cash share-based compensation expenses of $715, $604, $1,793 and $1,300, respectively)	1,854	1,415	3,896	2,948
Total operating costs and expenses	3,589	2,437	7,469	5,183
Loss from operations	(3,589)	(2,437)	(7,469)	(4,670)
Interest income	1		2	1
Net loss	(3,588)	(2,437)	(7,467)	(4,669)
Less: Net loss attributable to noncontrolling interest	(44)	(38)	(94)	(62)
Net loss attributable to common shareholders	$ (3,544)	$ (2,399)	$ (7,373)	$ (4,607)
Net loss per common share attributable to common shareholders:
Basic and diluted	$ (0.12)	$ (0.08)	$ (0.24)	$ (0.17)
Weighted average common shares outstanding:
Basic and diluted	30,152	28,669	30,138	26,888

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Research and Development Expense [Member]
Share-based payment arrangement, expense	$ 966	$ 447	$ 2,243	$ 737
General and Administrative Expense [Member]
Share-based payment arrangement, expense	$ 715	$ 604	$ 1,793	$ 1,300

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total Shareholders Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Oct. 31, 2020	$ 242,000	$ 200,355,000	$ (191,836,000)	$ 8,761,000	$ (497,000)	$ 8,264,000
Beginning balance, shares at Oct. 31, 2020	24,248,695
Stock option compensation to employees and directors		1,756,000		1,756,000		1,756,000
Stock options and warrants issued to consultants		282,000		282,000		282,000
Common stock issued pursuant to employee stock purchase plan		3,000		3,000		3,000
Common stock issued pursuant to employee stock purchase plan, shares	1,634
Net loss			(4,607,000)	(4,607,000)	(62,000)	(4,669,000)
Common stock issued upon exercise of stock options	$ 1,000	292,000		293,000		293,000
Common stock issued upon exercise of stock options, shares	107,451
Common stock issued in a public offering, net of offering expenses of $2,208	$ 44,000	20,248,000		20,292,000		20,292,000
Common stock issued in a public offering, net of offering expenses, shares	4,285,715
Common stock issued in at-the-market offering, net of offering expenses of $341	$ 28,000	10,806,000		10,834,000		10,834,000
Common stock issued in at-the-market offering, net of offering expenses, shares	2,806,410
Ending balance, value at Apr. 30, 2021	$ 315,000	233,742,000	(196,443,000)	37,614,000	(559,000)	37,055,000
Ending balance, shares at Apr. 30, 2021	31,449,905
Beginning balance, value at Jan. 31, 2021	$ 262,000	207,382,000	(194,044,000)	13,600,000	(521,000)	13,079,000
Beginning balance, shares at Jan. 31, 2021	26,179,122
Stock option compensation to employees and directors		881,000		881,000		881,000
Stock options and warrants issued to consultants		170,000		170,000		170,000
Common stock issued pursuant to employee stock purchase plan		3,000		3,000		3,000
Common stock issued pursuant to employee stock purchase plan, shares	1,634
Net loss			(2,399,000)	(2,399,000)	(38,000)	(2,437,000)
Common stock issued upon exercise of stock options	$ 1,000	189,000		190,000		190,000
Common stock issued upon exercise of stock options, shares	77,571
Common stock issued in a public offering, net of offering expenses of $2,208	$ 43,000	20,249,000		20,292,000		20,292,000
Common stock issued in a public offering, net of offering expenses, shares	4,285,715
Common stock issued in at-the-market offering, net of offering expenses of $341	$ 9,000	4,868,000		4,877,000		4,877,000
Common stock issued in at-the-market offering, net of offering expenses, shares	905,863
Ending balance, value at Apr. 30, 2021	$ 315,000	233,742,000	(196,443,000)	37,614,000	(559,000)	37,055,000
Ending balance, shares at Apr. 30, 2021	31,449,905
Beginning balance, value at Oct. 31, 2021	$ 301,000	239,927,000	(204,790,000)	35,438,000	(671,000)	34,767,000
Beginning balance, shares at Oct. 31, 2021	30,050,894
Stock option compensation to employees and directors		3,598,000		3,598,000		3,598,000
Stock options and warrants issued to consultants		437,000		437,000		437,000
Common stock issued to consultants	$ 1,000	63,000		64,000		64,000
Common stock issued to consultants, shares	20,000
Common stock issued pursuant to employee stock purchase plan		7,000		7,000		7,000
Common stock issued pursuant to employee stock purchase plan, shares	2,389
Net loss			(7,373,000)	(7,373,000)	(94,000)	(7,467,000)
Common stock issued upon exercise of stock options and warrants
Common stock issued upon exercise of stock options and warrants, shares	81,425
Ending balance, value at Apr. 30, 2022	$ 302,000	244,032,000	(212,163,000)	32,171,000	(765,000)	31,406,000
Ending balance, shares at Apr. 30, 2022	30,154,708
Beginning balance, value at Jan. 31, 2022	$ 301,000	242,281,000	(208,619,000)	33,963,000	(721,000)	33,242,000
Beginning balance, shares at Jan. 31, 2022	30,132,319
Stock option compensation to employees and directors		1,462,000		1,462,000		1,462,000
Stock options and warrants issued to consultants		219,000		219,000		219,000
Common stock issued to consultants	$ 1,000	63,000		64,000		64,000
Common stock issued to consultants, shares	20,000
Common stock issued pursuant to employee stock purchase plan		7,000		7,000		7,000
Common stock issued pursuant to employee stock purchase plan, shares	2,389
Net loss			(3,544,000)	(3,544,000)	(44,000)	(3,588,000)
Ending balance, value at Apr. 30, 2022	$ 302,000	$ 244,032,000	$ (212,163,000)	$ 32,171,000	$ (765,000)	$ 31,406,000
Ending balance, shares at Apr. 30, 2022	30,154,708

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2021
Statement of Stockholders' Equity [Abstract]
Expenses of the public offering	$ 2,208	$ 2,208
Net of offering expenses	$ 156	$ 341

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (7,467)	$ (4,669)
Stock option compensation to employees and directors	3,598	1,756
Stock options and warrants issued to consultants	437	282
Common stock issued to consultants	64
Gain on sale of equipment		(5)
Amortization of operating lease right-of-use asset	21	29
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(56)	(58)
Accounts payable	(44)	205
Accrued expenses	(37)	77
Operating lease liability	(19)	(29)
Net cash used in operating activities	(3,503)	(2,412)
Cash flows from investing activities:
Disbursements to acquire short-term investments	(4,249)	(10,399)
Proceeds from maturities of short-term investments	6,349	2,640
Proceeds from sale of equipment		35
Net cash provided by (used in) investing activities	2,100	(7,724)
Cash flows from financing activities:
Gross proceeds from sale of common stock in a public offering		22,500
Expenses of the public offering		(2,208)
Gross proceeds from sale of common stock in an at-the-market offering		11,175
Expenses of the at-the-market offering		(341)
Proceeds from sale of common stock pursuant to employee stock purchase plan	7	3
Proceeds from exercise of stock options		293
Net cash provided by financing activities	7	31,422
Net (decrease) increase in cash and cash equivalents	(1,396)	21,286
Cash and cash equivalents at beginning of period	29,128	6,417
Cash and cash equivalents at end of period	$ 27,732	$ 27,703

BUSINESS AND FUNDING

BUSINESS AND FUNDING	6 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
BUSINESS AND FUNDING	1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries. Our primary operations involve developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. Our therapeutics programs include (i) the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (“CAR-T”) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), and (ii) the discovery and ultimately development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Our vaccine programs include (i) the development of a preventative vaccine against triple negative breast cancer (“TNBC”), the most lethal form of breast cancer, as well other forms of breast cancer and (ii) a preventative vaccine against ovarian cancer. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading National Cancer Institute designated cancer research center, relating to Wistar’s chimeric endocrine receptor targeted therapy technology. We have initially focused on the development of a treatment for ovarian cancer, but we also may pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), is advancing toward human clinical testing of the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer. We received authorization from the U.S. Food and Drug Administration (“FDA”) in August 2021, to commence enrollment and treatment of patients in a Phase 1 clinical trial. We began patient recruitment for the trial in March 2022, and that process is ongoing. This study is a dose-escalation trial with two arms based on injection method—intraperitoneal or intravenous—to determine the maximum tolerated dose in patients with recurrent epithelial ovarian cancer and to assess persistence, expansion and efficacy of the modified T-cells. The study is being conducted at Moffitt and will consist of 24 to 48 patients who have received at least two prior lines of chemotherapy. The study is estimated to be completed in two to four years depending on multiple factors including when maximum tolerated dose is reached and the rate of patient recruitment. In April 2020, we entered into a collaboration with OntoChem GmbH (“OntoChem”) to discover and ultimately develop anti-viral drug candidates against COVID-19. Through this collaboration, we utilized advanced computational methods, machine learning, and molecular modeling techniques to perform in silico The screening process resulted in the identification of multiple compounds that could potentially disrupt critical enzymes of the virus, including the virus’ main protease, M pro in vitro In May 2021, after completion of the aforementioned animal studies, OntoChem assigned its rights and obligations related to this collaboration to MolGenie GmbH (“MolGenie”), a company spun-out from OntoChem focused on drug discovery and development. As a result of the MolGenie spin-out, there was no change in the personnel working on our project, and the assignment caused no interruptions to the program’s development. While use of preventative vaccines is widespread throughout much of the developed world, we believe that there is and will continue to be a need for effective treatments for COVID-19. We believe that there are a number of factors that have limited the effectiveness, both in the near and long term, of the vaccines currently in use, including, but not limited to, vaccine persistence, viral escape and perceptions of long-term safety resulting in vaccine resistance. Furthermore, there are currently two new anti-viral treatments, Pfizer’s Paxlovid, which is a combination therapy consisting of the protease-inhibitor nirmatrelvir and the antiretroviral ritonavir and Merck’s polymerase-inhibitor molnupiravir, that have recently been authorized for emergency use in the U.S. These treatments use oral formulations, while all other currently authorized or approved treatments require intravenous administration. As the main component of Pfizer’s treatment is a protease-inhibitor targeting M pro pro in vitro pro We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. Utilizing this technology, we are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused specifically on TNBC. The focus of this vaccine is a specific protein, α-lactalbumin, that is only expressed during lactation in a healthy mother’s mammary tissue. This protein disappears when the mother is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. Following the FDA’s authorization to proceed with clinical trials in December 2020, in October 2021, we commenced dosing patients in a Phase 1 clinical trial of our breast cancer vaccine. Funded by a U.S. Department of Defense grant, this study is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study is being conducted at Cleveland Clinic and will consist of 18 to 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. During the course of the study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. The study is roughly one-fourth of the way complete and is estimated to be completed by the end of calendar year 2022. Initial indications suggest that an immune response is being observed. In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. This technology pertains to among other things, the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor 2 protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines after menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. We entered into a joint development agreement with Cleveland Clinic to advance this vaccine toward human clinical testing. In May 2021, Cleveland Clinic was granted an award for our ovarian cancer vaccine technology by the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program will be used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and IND-enabling studies. This work will be performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the transfer of any rights to the Company’s assets. Over the next several quarters, we expect the development of our breast and ovarian cancer vaccines, our COVID-19 therapeutic discovery program and Certainty’s CAR-T technology to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities regarding its liquid biopsy platform and in the area of encrypted audio/video conference calling. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and vaccine programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current therapy or vaccine programs in the near term. Our strategy is to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of June 10, 2022, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. We may seek to obtain working capital during our fiscal year 2022 or thereafter through sales of our equity securities or through bank credit facilities or public or private debt from various financial institutions where possible. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we do identify sources for additional funding, the sale of additional equity securities or convertible debt will result in dilution to our stockholders. We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all. If we fail to obtain additional working capital as and when needed, such failure could have a material adverse impact on our business, results of operations and financial condition. Furthermore, such lack of funds may inhibit our ability to respond to competitive pressures or unanticipated capital needs, or may force us to reduce operating expenses, which would significantly harm the business and development of operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2021. The accompanying October 31, 2021 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April 30, 2022, and results of operations and cash flows for the interim periods represented. The results of operations for the three and six months ended April 30, 2022 are not necessarily indicative of the results to be expected for the entire year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the six months ended April 30, 2022 (in thousands): SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY Balance, October 31, 2021 $ (671 ) Net loss attributable to noncontrolling interest (94 ) Balance, April 30, 2022 $ (765 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100 Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, developing anti-viral drug candidates for COVID-19, developing our breast cancer vaccine, and developing our ovarian cancer vaccine, are expensed in the consolidated financial statements in the period incurred.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	6 Months Ended
	Apr. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	2. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company grants incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense The compensation cost for service-based stock options granted to employees and directors is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one four years 875,000 881,000 1,605,000 1,756,000 For stock options granted to employees and directors that vest based on market conditions, such as the trading price of the Company’s common stock exceeding certain price targets, we use a Monte Carlo Simulation in estimating the fair value at grant date and recognize compensation cost over the implied service period (median time to vest). On June 1, 2021, our Chairman and Chief Executive Officer and our President, Chief Operating Officer and Chief Financial Officer were awarded market condition stock options for 2,000,000 100,000 5.00 8.00 587,000 0 1,993,000 0 The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 109,000 132,000 218,000 186,000 Stock Option Plans During the three months ended April 30, 2022, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Stock Option Activity During the three months ended April 30, 2022 and 2021, we granted options to purchase 1,400,000 shares and 250,000 shares of common stock, respectively, and during the six months ended April 30, 2022 and 2021, we granted options to purchase 1,430,000 shares and 1,380,000 shares of common stock, respectively, to employees and consultants, with exercise prices ranging from $ 2.62 to $ 5.30 per share, pursuant to the 2018 Share Plan. During the three months ended April 30, 2022 and 2021, stock options to purchase 0 shares of common stock and 77,571 shares of common stock, net of 7,937 shares withheld on a cashless exercise, respectively, were exercised with aggregate proceeds of $ 0 and $ 0 , respectively. During the six months ended April 30, 2022 and 2021, stock options to purchase 46,909 shares of common stock, net of 53,091 shares withheld on a cashless exercise and 107,451 shares of common stock, net of 7,937 shares withheld on a cashless exercise, respectively, were exercised with aggregate proceeds of $ 0 and $ 0 , respectively. 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the six months ended April 30, 2022 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2021 1,1,718,634 $ 2.82 Exercised (100,000 ) $ 2.92 Options outstanding and exercisable at 1,618,634 $ 2.81 $ 1,182 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Exercisable Weighted Average (in years) Weighted $ 0.67 2.30 527,500 4.0 $ 1.54 $ 2.58 3.13 577,000 2.7 $ 2.76 $ 3.46 5.30 514,134 6.0 $ 4.16 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of April 30, 2022, the 2018 Share Plan had 600,000 SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2021 7,409,992 $ 3.76 Granted 1,430,000 $ 2.74 Options outstanding at April 30, 2022 8,839,992 $ 3.60 $ 1,371 Options exercisable at April 30, 2022 4,364,161 $ 3.63 $ 426 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Number Weighted (in years) Weighted Number Weighted (in years) Weighted $ 2.09 3.87 5,369,992 7.9 $ 3.24 3,298,050 7.0 $ 3.49 $ 3.96 5.30 3,470,000 8.5 $ 4.16 1,066,111 7.6 $ 4.07 Non-Plan Options In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors. Information regarding stock options that were granted outside of share plans for the six months ended April 30, 2022 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2021 1,642,000 $ 2.58 Options outstanding and exercisable at 1,642,000 $ 2.58 $ 1,108 The following table summarizes information about stock options outstanding and exercisable that were granted outside of share plans as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted $ 2.58 1,642,000 0.3 $ 2.58 Stock Awards For stock awards granted to employees, directors and consultants that vest upon grant, we recognize expense at the date of grant based on the grant date closing price of the underlying common stock. We did not grant any stock awards that vested upon grant during the six months ended April 30, 2022 or 2021. Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the “ESPP”) which permits eligible employees to purchase shares at not less than 85 2,389 1,634 7,000 3,000 Warrants On October 30, 2020, we issued a warrant, expiring on October 30, 2025 60,000 2.06 five months 38,000 96,000 25,484 On November 1, 2021 we issued a warrant, expiring on October 30, 2026 60,000 4.77 five months 110,000 220,000 As of April 30, 2022, we also had warrants outstanding to purchase 300,000 6.56 March 22, 2026

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	3. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 – Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 – Financial assets and liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the asset and liabilities. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2022: SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total (in thousands) Money market funds: Cash equivalents $ 25,294 $ - $ - $ 25,294 Certificates of deposit: Cash equivalents 2,250 - - 2,250 Short-term investments - 1,200 1,200 U. S. treasury bills Short-term investments - 3,299 - 3,299 Total financial assets $ 27,544 $ 4,499 $ - $ 32,043 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2021: Level 1 Level 2 Level 3 Total (in thousands) Money market funds: Cash equivalents $ 28,949 $ - $ - $ 28,949 Certificates of deposit: Short term investments - 2,000 - 2,000 U. S. treasury bills - Short-term investments - 4,599 - 4,599 Total financial assets $ 28,949 $ 6,599 $ - $ 35,548 The estimated fair value of prepaid expenses and other current assets and accounts payable approximates their individual carrying amounts due to the short-term nature of these instruments. Cash balances are stated at carrying value which approximates fair value.

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Apr. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES	4. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES April 30, October 31, 2022 2021 (in thousands) Payroll and related expenses $ 477 $ 492 Accrued royalty and contingent legal fees 577 577 Accrued other 3 26 Accrued expenses $ 1,057 $ 1,095

NET LOSS PER SHARE OF COMMON ST

NET LOSS PER SHARE OF COMMON STOCK	6 Months Ended
	Apr. 30, 2022
Net loss per common share attributable to common shareholders:
NET LOSS PER SHARE OF COMMON STOCK	5. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the six months ended April 30, 2022 and 2021, were stock options to purchase 12,100,626 8,813,626 360,000 860,000

EFFECT OF RECENTLY ADOPTED AND

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	6 Months Ended
	Apr. 30, 2022
Effect Of Recently Adopted And Issued Pronouncements
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	6. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard did not have a material impact on our condensed consolidated financial statements and related disclosures. In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our condensed consolidated financial statements and related disclosures. In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our condensed consolidated financial statements and related disclosures. In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our condensed consolidated financial statements and related disclosures.

INCOME TAXES

INCOME TAXES	6 Months Ended
	Apr. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	7. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382. We have no

LEASES

LEASES	6 Months Ended
	Apr. 30, 2022
Leases
LEASES	8. LEASES We lease approximately 2,000 September 30, 2021 5,000 3 260,000 10 17,000 16,000 33,000 32,000 For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments. The remaining 53 As of April 30, 2022, the annual minimum future lease payments of our operating lease liabilities were as follows: SCHEDULE of MINIMUM LEASE PAYMENTS For Periods Ended October 31, Operating (in thousands) 2022 $ 32 2023 66 2024 67 2025 70 2026 65 Total future minimum lease payments, undiscounted 300 Less: Imputed interest 59 Present value of future minimum lease payments $ 241

COMMITMENTS AND CONTINGENCES

COMMITMENTS AND CONTINGENCES	6 Months Ended
	Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCES	9. COMMITMENTS AND CONTINGENCES Litigation Matters Other than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. Impact of Coronavirus Pandemic The ongoing global outbreak of COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, and while the breadth of these measures has been reduced recently, the Company cannot predict their scope or the severity of the outbreak in the future, and these developments and measures could materially and adversely affect the Company’s business, the operations of the Company’s collaboration partners, and the Company’s results of operations and financial condition. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business and has taken steps to minimize its impact on the Company’s business. Although COVID-19 has not had a material adverse impact on the Company’s operations and its clinical and preclinical programs, the extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the occurrence of new mutations of the SARS-CoV-2 virus, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain the pandemic or mitigate its impact, among others. Certain of the Company’s collaboration partners have experienced shutdowns or other business disruptions. As a result, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Apr. 30, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	10. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four SCHEDULE of SEGMENT INFORMATION 2022 2021 2022 2021 For the Three Months Ended April 30, For the Six Months 2022 2021 2022 2021 Net Loss: CAR-T Therapeutics $ (1,399 ) $ (1,446 ) $ (3,010 ) $ (2,406 ) Cancer Vaccines (1,423 ) (662 ) (2,780 ) (1,569 ) Anti-Viral Therapeutics (757 ) (310 ) (1,661 ) (791 ) Other (9 ) (19 ) (16 ) 97 Total $ (3,588 ) $ (2,437 ) $ (7,467 ) $ (4,669 ) Net loss $ (3,588 ) $ (2,437 ) $ (7,467 ) $ (4,669 ) Total operating costs and expenses $ 3,589 $ 2,437 $ 7,469 $ 5,183 Less non-cash share-based compensation (1,681 ) (1,051 ) (4,036 ) (2,037 ) Operating costs and expenses excluding non-cash share-based compensation $ 1,908 $ 1,386 $ 3,433 $ 3,146 Operating costs and expenses excluding non-cash share based compensation: CAR-T Therapeutics $ 759 $ 935 $ 1,427 $ 1,492 Cancer Vaccines 740 299 1,220 837 Anti-Viral Therapeutics 402 138 774 409 Other 7 14 12 408 Total $ 1,908 $ 1,386 $ 3,433 $ 3,146 Operating costs and expenses excluding non-cash share based compensation expense $ 1,908 $ 1,386 $ 3,433 $ 3,146 April 30, October 31, Total assets: CAR-T Therapeutics $ 13,014 $ 15,068 Cancer Vaccines 12,680 13,276 Anti-Viral Therapeutics 6,883 7,368 Other 220 545 Total $ 32,797 $ 36,257 Total Asset $ 32,797 $ 36,257 Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise. The Company’s consolidated revenue of $ 513,000 385,000

BUSINESS AND FUNDING (Policies)

BUSINESS AND FUNDING (Policies)	6 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the year ended October 31, 2021. The accompanying October 31, 2021 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of April 30, 2022, and results of operations and cash flows for the interim periods represented. The results of operations for the three and six months ended April 30, 2022 are not necessarily indicative of the results to be expected for the entire year.
Noncontrolling Interest	Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the six months ended April 30, 2022 (in thousands): SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY Balance, October 31, 2021 $ (671 ) Net loss attributable to noncontrolling interest (94 ) Balance, April 30, 2022 $ (765 )
Revenue Recognition	Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these agreements were satisfied and 100
Cost of Revenues	Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.
Research and Development Expenses	Research and Development Expenses Research and development expenses, consisting primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing immuno-therapy drugs against cancer, developing anti-viral drug candidates for COVID-19, developing our breast cancer vaccine, and developing our ovarian cancer vaccine, are expensed in the consolidated financial statements in the period incurred.

BUSINESS AND FUNDING (Tables)

BUSINESS AND FUNDING (Tables)	6 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY	Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the six months ended April 30, 2022 (in thousands): SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY Balance, October 31, 2021 $ (671 ) Net loss attributable to noncontrolling interest (94 ) Balance, April 30, 2022 $ (765 )

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2021 1,642,000 $ 2.58 Options outstanding and exercisable at 1,642,000 $ 2.58 $ 1,108
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable that were granted outside of share plans as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted $ 2.58 1,642,000 0.3 $ 2.58
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2021 1,1,718,634 $ 2.82 Exercised (100,000 ) $ 2.92 Options outstanding and exercisable at 1,618,634 $ 2.81 $ 1,182
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Exercisable Weighted Average (in years) Weighted $ 0.67 2.30 527,500 4.0 $ 1.54 $ 2.58 3.13 577,000 2.7 $ 2.76 $ 3.46 5.30 514,134 6.0 $ 4.16
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2021 7,409,992 $ 3.76 Granted 1,430,000 $ 2.74 Options outstanding at April 30, 2022 8,839,992 $ 3.60 $ 1,371 Options exercisable at April 30, 2022 4,364,161 $ 3.63 $ 426
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of April 30, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Number Weighted (in years) Weighted Number Weighted (in years) Weighted $ 2.09 3.87 5,369,992 7.9 $ 3.24 3,298,050 7.0 $ 3.49 $ 3.96 5.30 3,470,000 8.5 $ 4.16 1,066,111 7.6 $ 4.07

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Apr. 30, 2022
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS	The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of April 30, 2022: SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total (in thousands) Money market funds: Cash equivalents $ 25,294 $ - $ - $ 25,294 Certificates of deposit: Cash equivalents 2,250 - - 2,250 Short-term investments - 1,200 1,200 U. S. treasury bills Short-term investments - 3,299 - 3,299 Total financial assets $ 27,544 $ 4,499 $ - $ 32,043 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2021: Level 1 Level 2 Level 3 Total (in thousands) Money market funds: Cash equivalents $ 28,949 $ - $ - $ 28,949 Certificates of deposit: Short term investments - 2,000 - 2,000 U. S. treasury bills - Short-term investments - 4,599 - 4,599 Total financial assets $ 28,949 $ 6,599 $ - $ 35,548

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Apr. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES April 30, October 31, 2022 2021 (in thousands) Payroll and related expenses $ 477 $ 492 Accrued royalty and contingent legal fees 577 577 Accrued other 3 26 Accrued expenses $ 1,057 $ 1,095

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Apr. 30, 2022
Leases
SCHEDULE of MINIMUM LEASE PAYMENTS	As of April 30, 2022, the annual minimum future lease payments of our operating lease liabilities were as follows: SCHEDULE of MINIMUM LEASE PAYMENTS For Periods Ended October 31, Operating (in thousands) 2022 $ 32 2023 66 2024 67 2025 70 2026 65 Total future minimum lease payments, undiscounted 300 Less: Imputed interest 59 Present value of future minimum lease payments $ 241

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2022
Segment Reporting [Abstract]
SCHEDULE of SEGMENT INFORMATION	SCHEDULE of SEGMENT INFORMATION 2022 2021 2022 2021 For the Three Months Ended April 30, For the Six Months 2022 2021 2022 2021 Net Loss: CAR-T Therapeutics $ (1,399 ) $ (1,446 ) $ (3,010 ) $ (2,406 ) Cancer Vaccines (1,423 ) (662 ) (2,780 ) (1,569 ) Anti-Viral Therapeutics (757 ) (310 ) (1,661 ) (791 ) Other (9 ) (19 ) (16 ) 97 Total $ (3,588 ) $ (2,437 ) $ (7,467 ) $ (4,669 ) Net loss $ (3,588 ) $ (2,437 ) $ (7,467 ) $ (4,669 ) Total operating costs and expenses $ 3,589 $ 2,437 $ 7,469 $ 5,183 Less non-cash share-based compensation (1,681 ) (1,051 ) (4,036 ) (2,037 ) Operating costs and expenses excluding non-cash share-based compensation $ 1,908 $ 1,386 $ 3,433 $ 3,146 Operating costs and expenses excluding non-cash share based compensation: CAR-T Therapeutics $ 759 $ 935 $ 1,427 $ 1,492 Cancer Vaccines 740 299 1,220 837 Anti-Viral Therapeutics 402 138 774 409 Other 7 14 12 408 Total $ 1,908 $ 1,386 $ 3,433 $ 3,146 Operating costs and expenses excluding non-cash share based compensation expense $ 1,908 $ 1,386 $ 3,433 $ 3,146 April 30, October 31, Total assets: CAR-T Therapeutics $ 13,014 $ 15,068 Cancer Vaccines 12,680 13,276 Anti-Viral Therapeutics 6,883 7,368 Other 220 545 Total $ 32,797 $ 36,257 Total Asset $ 32,797 $ 36,257

SCHEDULE OF NONCONTROLLING INTE

SCHEDULE OF NONCONTROLLING INTEREST AS A COMPONENT OF EQUITY (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Accounting Policies [Abstract]
Beginning balance			$ (671)
Net loss attributable to noncontrolling interest	$ (44)	$ (38)	(94)	$ (62)
Ending balance	$ (765)		$ (765)

BUSINESS AND FUNDING (Details N

BUSINESS AND FUNDING (Details Narrative)	6 Months Ended
	Apr. 30, 2022
Accounting Policies [Abstract]
Ownership percentage	5.00%
Revenue percentage	100.00%

SCHEDULE OF OPTION ACTIVITY (De

SCHEDULE OF OPTION ACTIVITY (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Apr. 30, 2022USD ($)$ / sharesshares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Options outstanding and Exercisable | shares	1,642,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance | $ / shares	$ 2.58
Shares, Options outstanding and Exercisable | shares	1,642,000
Weighted Average Exercise Price Per Share, Outstanding and Exercisable | $ / shares	$ 2.58
Aggregate Intrinsic Value, Outstanding and Exercisable | $	$ 1,108
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Options outstanding and Exercisable | shares	11,718,634
Weighted Average Exercise Price Per Share, Outstanding Beginning balance | $ / shares	$ 2.82
Shares, Options, Exercised | shares	(100,000)
Weighted Average Exercise Price Per Share, Exercised | $ / shares	$ 2.92
Shares, Options outstanding and Exercisable | shares	1,618,634
Weighted Average Exercise Price Per Share, Outstanding and Exercisable | $ / shares	$ 2.81
Aggregate Intrinsic Value, Outstanding and Exercisable | $	$ 1,182
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Options outstanding and Exercisable | shares	7,409,992
Weighted Average Exercise Price Per Share, Outstanding Beginning balance | $ / shares	$ 3.76
Shares, Options, Granted | shares	1,430,000
Weighted Average Exercise Price Per Share, Granted | $ / shares	$ 2.74
Shares, Options outstanding, Ending balance | shares	8,839,992
Weighted Average Exercise Price Per Share, Outstanding Ending balance | $ / shares	$ 3.60
Aggregate Intrinsic Value, Outstanding Ending balance | $	$ 1,371
Shares, Options outstanding, Exercisable | shares	4,364,161
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 3.63
Aggregate Intrinsic Value, Exercisable | $	$ 426

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE (Details) - $ / shares	6 Months Ended
	Apr. 30, 2022	Oct. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Outstanding		1,642,000
Weighted Average Exercise Price		$ 2.58
2010 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Outstanding		11,718,634
Weighted Average Exercise Price		$ 2.82
2010 Share Plan [Member] | Range 1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	$ 0.67
Range of Exercise Prices, Lower limit	$ 2.30
Number of Outstanding	527,500
Weighted Average Remaining Contractual Life (in years)	4 years
Weighted Average Exercise Price	$ 1.54
2010 Share Plan [Member] | Range 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	2.58
Range of Exercise Prices, Lower limit	$ 3.13
Number of Outstanding	577,000
Weighted Average Remaining Contractual Life (in years)	2 years 8 months 12 days
Weighted Average Exercise Price	$ 2.76
2010 Share Plan [Member] | Range 3 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	3.46
Range of Exercise Prices, Lower limit	$ 5.30
Number of Outstanding	514,134
Weighted Average Remaining Contractual Life (in years)	6 years
Weighted Average Exercise Price	$ 4.16
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Outstanding	8,839,992	7,409,992
Weighted Average Exercise Price	$ 3.60	$ 3.76
Number Exercisable, Options Exercisable	4,364,161
Weighted Average Exercise Price, Options Exercisable	$ 3.63
2018 Share Plan [Member] | Range 1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	2.09
Range of Exercise Prices, Lower limit	$ 3.87
Number of Outstanding	5,369,992
Weighted Average Remaining Contractual Life (in years)	7 years 10 months 24 days
Weighted Average Exercise Price	$ 3.24
Number Exercisable, Options Exercisable	3,298,050
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years
Weighted Average Exercise Price, Options Exercisable	$ 3.49
2018 Share Plan [Member] | Range 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower limit	3.96
Range of Exercise Prices, Lower limit	$ 5.30
Number of Outstanding	3,470,000
Weighted Average Remaining Contractual Life (in years)	8 years 6 months
Weighted Average Exercise Price	$ 4.16
Number Exercisable, Options Exercisable	1,066,111
Weighted Average Remaining Contractual Life (in years), Options Exercisable	7 years 7 months 6 days
Weighted Average Exercise Price, Options Exercisable	$ 4.07
Outside of Plans [Member] | Range 1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted Average Remaining Contractual Life (in years)	3 months 18 days
Weighted Average Exercise Price	$ 2.58
Range of Exercise Prices	2.58
Number of Options Outstanding and Exercisable	1,642,000

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Nov. 16, 2021	Nov. 02, 2021	Jun. 01, 2021	Oct. 30, 2020	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Issued During Period, Value, Stock Options Exercised						$ 190,000		$ 293,000
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock Issued During Period, Value, Stock Options Exercised						1,000		1,000
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period		5 months		5 months
Class of warrant or right, date from which warrants or rights exercisable		Oct. 30, 2026		Oct. 30, 2025
Warrants purchase of common stock		60,000		60,000
Warrant exercise price		$ 4.77		$ 2.06	$ 6.56		$ 6.56
Consulting expense	$ 25,484				$ 110,000	$ 38,000	$ 220,000	$ 96,000
Warrants to purchase common stock					300,000		300,000
Warrants maturity date					Mar. 22, 2026		Mar. 22, 2026
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted							1,430,000
Number of shares available for future grants					600,000		600,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option to purchase common stock					2,389	1,634	7,000	3,000
Purchase price of common stock percentage							85.00%
Equity Option [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted			2,000,000
Equity Option [Member] | 2018 Share Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted			100,000
Non Vested Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation					$ 587,000	$ 0	$ 1,993,000	$ 0
Stock Option Activity [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option to purchase common stock					0	77,571	46,909	107,451
[custom:SharesWithheldOnCashlessExercise]						7,937	53,091	7,937
Stock Issued During Period, Value, Stock Options Exercised					$ 0	$ 0	$ 0	$ 0
Minimum [Member] | Equity Option [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price			$ 5
Maximum [Member] | Equity Option [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price			$ 8
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation					875,000	881,000	$ 1,605,000	1,756,000
Employees and Directors [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period							1 year
Employees and Directors [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period							4 years
Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted					$ 109,000	$ 132,000	$ 218,000	$ 186,000
Employees and Consultants [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted					1,400,000	250,000	1,430,000	1,380,000
Employees and Consultants [Member] | Minimum [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price					$ 2.62		$ 2.62
Employees and Consultants [Member] | Maximum [Member] | 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price					$ 5.30		$ 5.30

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents	$ 25,294	$ 28,949
Certificates of deposit: Cash and cash equivalents	2,250
Certificates of deposit: Short-term investments	1,200	2,000
US Treasury bills Short-term investments	3,299	4,599
Total financial assets	32,043	35,548
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents	25,294	28,949
Certificates of deposit: Cash and cash equivalents	2,250
Certificates of deposit: Short-term investments
US Treasury bills Short-term investments
Total financial assets	27,544	28,949
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Certificates of deposit: Short-term investments	1,200	2,000
US Treasury bills Short-term investments	3,299	4,599
Total financial assets	4,499	6,599
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds: Cash and cash equivalents
Certificates of deposit: Cash and cash equivalents
Certificates of deposit: Short-term investments
US Treasury bills Short-term investments
Total financial assets

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Apr. 30, 2022	Oct. 31, 2021
Payables and Accruals [Abstract]
Payroll and related expenses	$ 477	$ 492
Accrued royalty and contingent legal fees	577	577
Accrued other	3	26
Accrued expenses	$ 1,057	$ 1,095

NET LOSS PER SHARE OF COMMON _2

NET LOSS PER SHARE OF COMMON STOCK (Details Narrative) - shares	6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	12,100,626	8,813,626
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	360,000	860,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Apr. 30, 2022	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits, penalties	$ 0	$ 0

SCHEDULE of MINIMUM LEASE PAYME

SCHEDULE of MINIMUM LEASE PAYMENTS (Details) $ in Thousands	Apr. 30, 2022USD ($)
Leases
2022	$ 32
2023	66
2024	67
2025	70
2026	65
Total future minimum lease payments, undiscounted	300
Less: Imputed interest	59
Present value of future minimum lease payments	$ 241

LEASES (Details Narrative)

LEASES (Details Narrative)	3 Months Ended		6 Months Ended
	Apr. 30, 2022USD ($)ft²	Apr. 30, 2021USD ($)	Apr. 30, 2022USD ($)ft²	Apr. 30, 2021USD ($)
Payments for rent	$ 17,000	$ 16,000	$ 33,000	$ 32,000
Almaden Expressway San Jose [Member]
Area of land | ft²	2,000		2,000
Lease expiration date			Sep. 30, 2021
Payments for rent			$ 5,000
Rent percentage			3.00%
Right of use asset obtained in exchange for operating lease liability			$ 260,000
Operating lease weighted average discount rate percent	10.00%		10.00%
Lessee operating lease term of contract	53 months		53 months

SCHEDULE of SEGMENT INFORMATION

SCHEDULE of SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021	Oct. 31, 2021
Segment Reporting Information [Line Items]
Net loss	$ (3,588)	$ (2,437)	$ (7,467)	$ (4,669)
Total operating costs and expenses	3,589	2,437	7,469	5,183
Less non-cash share-based compensation	(1,681)	(1,051)	(4,036)	(2,037)
Operating costs and expenses excluding non-cash share based compensation expense	1,908	1,386	3,433	3,146
Total Asset	32,797		32,797		$ 36,257
Cart Therapeutics [Member]
Segment Reporting Information [Line Items]
Net loss	(1,399)	(1,446)	(3,010)	(2,406)
Operating costs and expenses excluding non-cash share based compensation expense	759	935	1,427	1,492
Total Asset	13,014		13,014		15,068
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Net loss	(1,423)	(662)	(2,780)	(1,569)
Operating costs and expenses excluding non-cash share based compensation expense	740	299	1,220	837
Total Asset	12,680		12,680		13,276
Anti Viral Therapeutics [Member]
Segment Reporting Information [Line Items]
Net loss	(757)	(310)	(1,661)	(791)
Operating costs and expenses excluding non-cash share based compensation expense	402	138	774	409
Total Asset	6,883		6,883		7,368
Other [Member]
Segment Reporting Information [Line Items]
Net loss	(9)	(19)	(16)	97
Operating costs and expenses excluding non-cash share based compensation expense	7	$ 14	12	$ 408
Total Asset	$ 220		$ 220		$ 545

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	6 Months Ended
	Apr. 30, 2022USD ($)Numbers
Segment Reporting [Abstract]
Number of reportable segments | Numbers	4
Revenues	$ 513,000
Royalty expense	$ 385,000